42PRibociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). (25th November 2018) - Masuda, N; Noguchi, S; Ishikawa, T; Aruga, T; Kim, S J; Toyama, T; Saeki, T; Saito, M; Yamanaka, T; Watanabe, J; Nakamura, S; Takahashi, M; et al.